F8 and hemophilia: Personalization in management may also help to ensure that PwSHA are treated with appropriate hemostatic treatments and reduce the utilization of on‐demand FVIII treatment regimens, which were still being utilized in 8% of PwSHA overall, including more than 10% of PwSHA and transfusion‐transmitted infections, rather than prophylaxis, which is the standard of care for all patients with severe hemophilia [10] and has been demonstrated to reduce bleeding events and HRU [15, 43].